

FIG.1A




FIG.1F



FIG.1B




FIG.1C



FIG. 1D1




FIG. 1D2



FIG. 1E1



FIG. 1E2




FIG. 1G1





FIG. 1G2

pHEX<sup>lac</sup>


CONDITIONED MEDIUM



$\beta$ -Hex X-CORRECTS



conditioned medium



control plain medium

FIG.2A

FIG.2B

VSV-G PSEUDOTYPED FIV(Hex)





FIG.3

FIV (Hex)




FIG.4

FIV (Hex) 6.2 maxi prep      Total 1mg  
1kb<sup>+</sup> uncut Sca I Not I Sal I Xho I 1kb<sup>+</sup>      (1μg/μl)




FIG.5




FIG.6






FIG.7




FIG.8






FIG.9



**FIG. 10**




FIG.11




FIG. 11A




FIG. 11B




FIG.12

$\beta$ -Hex<sup>XAT</sup>




FIG.13






FIG.14




FIG.15

Hex<sup>XAT</sup>: Excisionally activated  $\beta$ -hexosaminidase gene




FIG.16A




FIG.16B

FIG.16C

Hex<sup>XAT</sup>: EXCISIONALLY ACTIVATED  $\beta$ -HEXOSAMINIDASE GENE




FIG.17A

Hex<sup>XAT</sup>: EXCISIONALLY ACTIVATED  $\beta$ -HEXOSAMINIDASE GENE




FIG.17B




FIG.17C




FIG.18

GM<sub>2</sub> ganglioside immunocytochemistry




FIG.19






FIG.20



PERINATAL GENE THERAPY IN  $\text{hexB}^{-/-}$  MICE





FIG.21

Perinatal FIV(Hex) in hexB<sup>-/-</sup>



5 wks old

FIG.22




FIG.23




FIG. 24






FIG. 26





FIG. 27






FIG. 28






FIG. 29




FIG. 30




FIG. 31




FIG. 32